Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)

Kessler, Torsten; Schliemann, Christoph; Hartmann, Wolfgang; Kirsch, Anna; Müller-Tidow, Carsten; Brümmendorf, Tim Henrik; Koschmieder, Steffen; Pohlen, Michele; Mikesch, Jan-Henrik; Vehring, Kerstin; Berdel, Wolfgang E.; Wardelmann, Eva; von Stillfried, Saskia; Lenz, Georg; Crysandt, Martina; Bormann, Eike; Stelljes, Matthias; Gerss, Joachim

doi:pmid:30903275

%0 Journal Article
%A Kessler, Torsten
%A Koschmieder, Steffen
%A Schliemann, Christoph
%A Crysandt, Martina
%A Mikesch, Jan-Henrik
%A von Stillfried, Saskia
%A Stelljes, Matthias
%A Pohlen, Michele
%A Lenz, Georg
%A Kirsch, Anna
%A Vehring, Kerstin
%A Wardelmann, Eva
%A Hartmann, Wolfgang
%A Bormann, Eike
%A Gerss, Joachim
%A Brümmendorf, Tim Henrik
%A Müller-Tidow, Carsten
%A Berdel, Wolfgang E.
%T Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
%J Annals of hematology
%V 98
%N 6
%@ 1432-0584
%C Berlin ; Heidelberg ; New York
%I Springer
%M RWTH-CONV-240230
%P 1393-1401
%D 2019
%F PUB:(DE-HGF)16
%9 Journal Article
%U <Go to ISI:>//WOS:000467682000007
%$ pmid:30903275
%R 10.1007/s00277-019-03651-9
%U https://publications.rwth-aachen.de/record/772696

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines